November 2009Forbes magazine named China Biologic to its annual list of Asia's "200 Best Under a Billion."
July 2009China Biologic acquired a 35% equity interest in Xi'an Huitian Blood Products Co., Ltd. (“Huitian”), gaining access to three new plasma stations with 80 metric tons in annual plasma collection volume and one plasma manufacturing facility with a 200 metric ton capacity.
December 2008China Biologic acquired 90% controlling interest in Guiyang Dalin Biologic Technologies Co., Ltd., which owned 54% equity interests in Guiyang Qianfeng Biological Products Co., Ltd. (“Qianfeng”), one of the largest plasma-based biopharmaceutical companies in China with 250 metric tons s in annual plasma collection volume and one plasma manufacturing facility with a 400 metric ton capacity. Qianfeng changed its name to Guizhou Taibang Biological Products Co.,Ltd. later.
August 2008Shandong Taibang completed the construction of an additional fractionation facility, renewed its GMP Certification, and more than doubled its annual production capacity to 700 metric tons of plasma.
|FirstPage | PreviousPage | NextPage | LastPage||CurrentPageIndex：6       |